The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Resolving the fibrotic niche of human liver cirrhosis at single-cell level
Open accessPublished version of a preprint
Abstract
Liver cirrhosis is a major cause of death worldwide and is characterized by extensive fibrosis. There are currently no effective antifibrotic therapies available. To obtain a better understanding of the cellular and molecular mechanisms involved in disease pathogenesis and enable the discovery of therapeutic targets, here we profile the transcriptomes of more than 100,000 single human cells, yielding molecular definitions for non-parenchymal cell types that are found in healthy and cirrhotic human liver. We identify a scar-associated TREM2+CD9+ subpopulation of macrophages, which expands in liver fibrosis, differentiates from circulating monocytes and is pro-fibrogenic. We also define ACKR1+ and PLVAP+ endothelial cells that expand in cirrhosis, are topographically restricted to the fibrotic niche and enhance the transmigration of leucocytes. Multi-lineage modelling of ligand and receptor interactions between the scar-associated macrophages, endothelial cells and PDGFRα+ collagen-producing mesenchymal cells reveals intra-scar activity of several pro-fibrogenic pathways including TNFRSF12A, PDGFR and NOTCH signalling. Our work dissects unanticipated aspects of the cellular and molecular basis of human organ fibrosis at a single-cell level, and provides a conceptual framework for the discovery of rational therapeutic targets in liver cirrhosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Focusing our analysis on the CD4+ T cell compartment, we identified FOXP3+ cells expressing canonical Treg cell transcripts, including IL2RA, CTLA4 and TNFRSF18 (Fig. 1D, right panel).”
From Regulatory T cells safeguard liver health during metabolic-associated steatohepatitis (2026) · cites this paper as [22]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“are equivalent to the scar-associated macrophages (SAM) in human MASH (6–8)”
From Lipid-associated macrophages' promotion of fibrosis resolution during MASH regression requires TREM2 (2024) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, conditioned media from TREM2+ SAM were reported to be more fibrogenic compared to their TREM2− non-scar-associated counterparts (6).”
From Lipid-associated macrophages' promotion of fibrosis resolution during MASH regression requires TREM2 (2024) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“that are characteristics of SAM described in humans (6, 7).”
From Lipid-associated macrophages' promotion of fibrosis resolution during MASH regression requires TREM2 (2024) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The growing accessibility of single-cell transcriptomics has also revealed the presence of numerous subsets/states of macrophages in any given injured tissue in humans (30–33).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [31]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the precise roles of the different subsets generated during injury and resolution are still under investigation, the prevailing dogma is that during active fibrogenesis, the macrophage pool is dominated by pro-inflammatory and pro-fibrogenic macrophages (31, 89, 90).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A good example of this is the population of macrophages in the fibrotic liver, which have been called LAMs, SAMs, and NAMs in different studies, despite largely sharing a conserved transcriptional profile (31, 104, 108).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“these cells also produce mediators such as SPP1 and TGF-β that activate HSCs and hence may promote fibrogenesis (31).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably, these cells exhibit a very similar transcriptional profile, with the precise name (LAM, SAM, or NAM) reflecting the different studies in which these cells were identified.”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Single-cell RNA-seq studies conducted by independent groups have identified, in human MASLD, macrophage subsets largely analogous to those previously described in mouse (196–198). These include resident KCs (VSIG4+/CD163+/MARCO+/TIMD4+), Mo-KCs (VSIG4+/CD163+/MARCO-/TIMD4-), LAMs (VSIG4-/TREM2+/CD9+) and C-LAMs (VSIG4-/CX3CR1+/CCR2+).”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [198]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While sub-populations of macrophages and HSCs in the healthy human liver have been described in single-cell data10–12, these subpopulations, and potential gene expression variations within, have not been resolved within the lobule organization at single-cell resolution in the human liver.”
From Spatial transcriptomics of healthy and fibrotic human liver at single-cell resolution (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“and fibrotic scars (SAM) (6)”
From Lipid-associated macrophages' promotion of fibrosis resolution during MASH regression requires TREM2 (2024) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“On the other hand, those monocytes recruited to zones of steatosis and fibrosis appear to take on an alternative profile, which has been given multiple names, including lipid-associated macrophages (LAMs), scar-associated macrophages (SAMs) and NASH-associated macrophages (NAMs) (31, 104, 108, 109).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [31]
The cited source says what the claim attributes to it.
In the citing paper
“Recent single-cell human liver studies have largely focused on chronic liver disease rather than ALF, with emphasis on non-parenchymal cell populations7–9”
From Multimodal decoding of human liver regeneration (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Notably, TREM2+/CD9+ macrophages have been shown to exhibit a pro-fibrogenic phenotype and to accumulate within collagen-rich fibrotic niches in cirrhotic livers, leading to their designation as scar associated macrophages (SAMs) (198).”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [198]
The cited source says what the claim attributes to it.
In the citing paper
“except for the mere recognition as a marker of fibrosis-associated macrophages39,43–45, the role of TREM2 in regulating the pro-fibrotic AM phenotype in lung fibrosis remains unclear.”
From TREM2 promotes lung fibrosis via controlling alveolar macrophage survival and pro-fibrotic activity (2025) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“In the liver, a TREM2+CD9+ subset of macrophages that differentiate from circulating monocytes expands during liver cirrhosis and contributes to fibrosis (Ramachandran et al., 2019).”
From TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy (2020) · cites this paper as Ramachandran et al., 2019
The cited source says what the claim attributes to it.
In the citing paper
“Both macrophage populations were identified by expression of CD74, while Mac 2 cells also expressed CD5L and MARCO (Fig. 2d, i; Supplementary Fig. 6b), most consistent with non-inflammatory macrophages or Kupffer cells10,11,21.”
From Spatial transcriptomics of healthy and fibrotic human liver at single-cell resolution (2025) · cites this paper as [11]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Notably, the Treg frequency was significantly elevated in MASH livers relative to that of controls (Fig. 1E), echoing the Treg enrichment observed in the CDAHFD and AMLN models.”
From Regulatory T cells safeguard liver health during metabolic-associated steatohepatitis (2026) · cites this paper as [22]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“PDGFRB expression was concentrated along the edges of ALDOB-expressing hepatocytes in a distribution expected for HSCs, which are located in the subendothelial space11 (Supplementary Fig. 2a–f).”
From Spatial transcriptomics of healthy and fibrotic human liver at single-cell resolution (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredIn the citing paper
“In the cirrhosis-enriched neighbourhoods, we recovered over-expression of known markers of scar-associated endothelium, including ACKR1 and PLVAP (Fig 5F) [2].”
From Differential abundance testing on single-cell data using k-nearest neighbor graphs (2022) · cites this paper as [2]
In the citing paper
“In addition to providing a first-of-its-kind liver cell atlas, this study revealed the presence of two disease-associated endothelial cell populations in the fibrotic niche, characterized as CD34+PLVAP+VWA1+ and CD34+PLVAP+ACKR1+ populations.”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · cites this paper as [335]
In the citing paper
“Moreover, this same study identified PDGFRA as a marker of scar-associated fibroblasts in cirrhotic livers.”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · cites this paper as [335]
In the citing paper
“One landmark study described the fibrotic niche in healthy and cirrhotic human livers via single-cell RNA sequencing [335].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · cites this paper as [335]
In the citing paper
“ScRNAseq of human cirrhotic livers has identified a subset of TREM2+CD9+ macrophages enriched in heavily scarred regions of the liver that secrete cytokines and growth factors, including epidermal growth factor (EGF) and platelet-derived growth factor BB (PDGF-BB) to create a pro-fibrogenic niche for aHSCs (56).”
From Hepatic Stellate Cell-Immune Interactions in NASH (2022) · cites this paper as [56]
In the citing paper
“This population was found to associate closely with aHSCs and likely overlaps with the scar-associated TREM2+ CD9+ macrophages described by Ramachandran et al. in scRNAseq of human cirrhosis (20, 56).”
From Hepatic Stellate Cell-Immune Interactions in NASH (2022) · cites this paper as [56]
In the citing paper
“Separately, fibrogenic TREM2+CD9+ “scar-associated” macrophages have been characterized in human cirrhosis (56).”
From Hepatic Stellate Cell-Immune Interactions in NASH (2022) · cites this paper as [56]
In the citing paper
“In silico trajectory analysis, based on spliced vs. unspliced mRNA ratios, suggested that these cells were derived from blood monocytes.”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [75]
In the citing paper
“Immunofluorescence staining demonstrated that these TREM2+/CD9+ macrophages were highly enriched in the fibrotic niche.”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [75]
In the citing paper
“Ramachandran et al. used scRNAseq technology to identify a disease-associated TREM2+/CD9+ macrophage population that was significantly expanded in human cirrhotic livers.”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [75]
In the citing paper
“Ligand-receptor pairs were localised to the fibrotic niche between scar-associated macrophages expressing TNFSF12 and PDGFB with myofibroblast receptors TNFSF12A and PDGFRA, respectively.”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [75]
In the citing paper
“Gene ontology of the top differentially expressed genes identified pro-fibrogenic factors, such as IL-1B, TREM2 (triggering receptor expressed on myeloid cells 2), CXCR4, C-C motif chemokine receptor (CCR)2, CXCL8, TNFSF12 and vascular endothelial growth factor (VEGF)A, which regulate scar-producing myofibroblasts, upregulate inflammation and promote angiogenesis.”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [75]
In the citing paper
“Analysis of the transcriptome of these scar-associated macrophages demonstrated a phenotype analogous to TREM2+/CD9+ BMDMs in mice.”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [75]
In the citing paper
“Cognate, pro-fibrotic myofibroblast receptors were also identified for secreted phosphoprotein 1 and IL1β.75”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [75]
In the citing paper
“Ramachandran et al. used this approach to identify a distinct population of scar-associated mesenchymal cells in the human liver expressing high levels of fibrogenic genes and the myofibroblast marker, PDGFRA. These myofibroblasts were topographically restricted to fibrotic septae and ligand-receptor analysis revealed a number of pro-fibrogenic pathways including TNFRSF12A, PDGFR and Notch. These”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [75]
In the citing paper
“Scar-associated LSECs have been shown by scRNAseq to expand in human cirrhosis. These cells have a PLVAP+ and ACKR1+ transcriptome and demonstrate a number of pro-inflammatory ligand-receptor interactions, such as TGFB1-TGFBR3, JAG1-NOTCH1 and CCL2-ACKR1.75”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [75]
In the citing paper
“Seminal work from the Henderson group first profiled hepatic cells, including HSCs from fibrotic mouse and patient livers (50, 51), which has since been expanded to MASH by several other groups including ours.”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [51]
In the citing paper
“LAMs are identified by the expression of TREM2, Tetraspanin CD9 (CD9), and SPP1, which also represent markers of scar-associated macrophages (SAMs) in cirrhotic patients, suggesting a common macrophage lineage in different liver injury models (51).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [51]
In the citing paper
“Animal models implicate HSCs and immune cells, especially macrophages, as major cellular drivers of extracellular matrix turnover, both through reduced secretion of ECM components and crosslinking enzymes as well as increased secretion of proteases and their inhibitors (51, 52, 64, 262, 270-274).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [51]
In the citing paper
“Mature and plasma B‐cell clusters have been also detected by sc‐RNAseq within areas of scarring in fibrotic livers of patients with cirrhosis.( 58 )”
From The Emerging Role of B Cells in the Pathogenesis of NAFLD (2021) · cites this paper as [58]
In the citing paper
“While many of these discoveries have been based on mouse models, scRNA-seq analyses from human livers have also identified SAMs as a unique population located in the fibrotic niche of cirrhotic livers of different disease aetiologies.74”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [74]
In the citing paper
“Increasingly sophisticated experimental approaches have allowed discovery of significant diversity and functional heterogeneity within the fibroblast population during organ fibrosis22–25 .”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [22]
In the citing paper
“a single-cell census of the colonic mesenchyme revealed four subsets of fibroblasts in addition to pericytes and myofibroblasts, and identification of a fibroblast subpopulation proximal to the colonic crypt niche which expressed SOX6, F3 (CD142), and WNT genes essential for colonic epithelial stem cell function.”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [22]
In the citing paper
“In colitis, this niche became dysregulated with emergence of an activated mesenchymal population expressing TNFSF14, fibroblastic reticular cell-associated genes, interleukin (IL)-33, and lysyl oxidases (LOX) leading to impaired epithelial proliferation and maturation”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fiji: an open-source platform for biological-image analysis
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012) · Nature Methods · doi:10.1038/nmeth.2019 · Cited by 66,890
Robust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
QuPath: Open source software for digital pathology image analysis
Bankhead, P., Loughrey, M. B., Fernández, J. A., Dombrowski, Y., McArt, D. G., Dunne, P. D., McQuaid, S., Gray, R. T., Murray, L. J., Coleman, H. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17204-5 · Cited by 8,908
Trapnell, C., Cacchiarelli, D., Grimsby, J., Pokharel, P., Li, S., Morse, M., Lennon, N. J., Livak, K. J., Mikkelsen, T. S., & Rinn, J. L. (2014) · Nature Biotechnology · doi:10.1038/nbt.2859 · Cited by 7,314
Spatial reconstruction of single-cell gene expression data
Satija, R., Farrell, J. A., Gennert, D., Schier, A. F., & Regev, A. (2015) · Nature Biotechnology · doi:10.1038/nbt.3192 · Cited by 7,055
Scenic: single-cell regulatory network inference and clustering.
Aibar, S., González-Blas, C. B., Moerman, T., Huynh-Thu, V. A., Imrichova, H., Hulselmans, G., Rambow, F., Marine, J.-C., Geurts, P., Aerts, J., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4463 · Cited by 6,520
Macrophage biology in development, homeostasis and disease
Wynn, T. A., Chawla, A., & Pollard, J. W. (2013) · Nature · doi:10.1038/nature12034 · Cited by 4,684
Self-citationMechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Cited by
Sorted by citations
Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages
Merad, M., & Martin, J. C. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0331-4 · Cited by 2,472
Fibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868
Self-citationLiver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
Transfer learning enables predictions in network biology
Theodoris, C. V., Xiao, L., Chopra, A., Chaffin, M. D., Al Sayed, Z. R., Hill, M. C., Mantineo, H., Brydon, E. M., Zeng, Z., Liu, X. S., et al. (2023) · Nature · doi:10.1038/s41586-023-06139-9 · Cited by 1,193
Differential abundance testing on single-cell data using k-nearest neighbor graphs
Dann, E., Henderson, N. C., Teichmann, S. A., Morgan, M. D., & Marioni, J. C. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-01033-z · Cited by 938
Self-citationSpatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches
Guilliams, M., Bonnardel, J., Haest, B., Vanderborght, B., Wagner, C., Remmerie, A., Bujko, A., Martens, L., Thoné, T., Browaeys, R., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.018 · Cited by 985
Hepatic inflammatory responses in liver fibrosis
Hammerich, L., & Tacke, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00807-x · Cited by 803
Self-citationDecoding myofibroblast origins in human kidney fibrosis
Kuppe, C., Ibrahim, M. M., Kranz, J., Zhang, X., Ziegler, S., Perales-Patón, J., Jansen, J., Reimer, K. C., Smith, J. R., Dobie, R., et al. (2021) · Nature · doi:10.1038/s41586-020-2941-1 · Cited by 769
Self-citationWen, Y., Lambrecht, J., Ju, C., & Tacke, F. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00558-8 · Cited by 695
Self-citationMechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis
Schwabe, R. F., Tabas, I., & Pajvani, U. B. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.311 · Cited by 671
Macrophages in health and disease
Park, M. D., Silvin, A., Ginhoux, F., & Merad, M. (2022) · Cell · doi:10.1016/j.cell.2022.10.007 · Cited by 644
TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy
Molgora, M., Esaulova, E., Vermi, W., Hou, J., Chen, Y., Luo, J., Brioschi, S., Bugatti, M., Omodei, A. S., Ricci, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.013 · Cited by 656
Tissue-specific macrophages: how they develop and choreograph tissue biology
Mass, E., Nimmerjahn, F., Kierdorf, K., & Schlitzer, A. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00848-y · Cited by 621
Remmerie, A., Martens, L., Thoné, T., Castoldi, A., Seurinck, R., Pavie, B., Roels, J., Vanneste, B., De Prijck, S., Vanhockerhout, M., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.08.004 · Cited by 592
Immune cell-mediated features of non-alcoholic steatohepatitis
Huby, T., & Gautier, E. L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00639-3 · Cited by 573
Targeting fibrosis: mechanisms and clinical trials
Zhao, M., Wang, L., Wang, M., Zhou, S., Lu, Y., Cui, H., Racanelli, A. C., Zhang, L., Ye, T., Ding, B., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01070-3 · Cited by 547
Determinants of resident tissue macrophage identity and function
Blériot, C., Chakarov, S., & Ginhoux, F. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.014 · Cited by 507
Govaere, O., Cockell, S., Tiniakos, D., Queen, R., Younes, R., Vacca, M., Alexander, L., Ravaioli, F., Palmer, J., Petta, S., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aba4448 · Cited by 479
Seidman, J. S., Troutman, T. D., Sakai, M., Gola, A., Spann, N. J., Bennett, H., Bruni, C. M., Ouyang, Z., Li, R. Z., Sun, X., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.001 · Cited by 443
Single-cell transcriptomics uncovers zonation of function in the mesenchyme during liver fibrosis
Dobie, R., Wilson-Kanamori, J. R., Henderson, B. E. P., Smith, J. R., Matchett, K. P., Portman, J. R., Wallenborg, K., Picelli, S., Zagorska, A., Pendem, S. V., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.024 · Cited by 420
Self-citationMetabolic reprogramming in liver fibrosis
Horn, P., & Tacke, F. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.05.003 · Cited by 432
Self-citationHepatic fibrosis 2022: Unmet needs and a blueprint for the future
Friedman, S. L., & Pinzani, M. (2022) · Hepatology · doi:10.1002/hep.32285 · Cited by 430
The Power of Plasticity—Metabolic Regulation of Hepatic Stellate Cells
Trivedi, P., Wang, S., & Friedman, S. L. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.10.026 · Cited by 427
Liver macrophages in health and disease
Guilliams, M., & Scott, C. L. (2022) · Immunity · doi:10.1016/j.immuni.2022.08.002 · Cited by 395
Tran, S., Baba, I., Poupel, L., Dussaud, S., Moreau, M., Gélineau, A., Marcelin, G., Magréau-Davy, E., Ouhachi, M., Lesnik, P., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.003 · Cited by 400
Colonna, M. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00837-1 · Cited by 394
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets
Guan, F., Wang, R., Yi, Z., Luo, P., Liu, W., Xie, Y., Liu, Z., Xia, Z., Zhang, H., & Cheng, Q. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02124-y · Cited by 371
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
Llovet, J. M., Willoughby, C. E., Singal, A. G., Greten, T. F., Heikenwälder, M., El-Serag, H. B., Finn, R. S., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00754-7 · Cited by 354
Identification of a broadly fibrogenic macrophage subset induced by type 3 inflammation
Fabre, T., Barron, A. M. S., Christensen, S. M., Asano, S., Bound, K., Lech, M. P., Wadsworth, M. H., Chen, X., Wang, C., Wang, J., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.add8945 · Cited by 355
Self-citationAlcohol-associated liver disease
Mackowiak, B., Fu, Y., Maccioni, L., & Gao, B. (2024) · Journal of Clinical Investigation · doi:10.1172/jci176345 · Cited by 359
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Tacke, F., Puengel, T., Loomba, R., & Friedman, S. L. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.038 · Cited by 321
Self-citationAndrews, T. S., Atif, J., Liu, J. C., Perciani, C. T., Ma, X., Thoeni, C., Slyper, M., Eraslan, G., Segerstolpe, A., Manuel, J., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1854 · Cited by 307
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Francque, S., Szabo, G., Abdelmalek, M. F., Byrne, C. D., Cusi, K., Dufour, J.-F., Roden, M., Sacks, F., & Tacke, F. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00366-5 · Cited by 316
Self-citationLiver regeneration and inflammation: from fundamental science to clinical applications
Campana, L., Esser, H., Huch, M., & Forbes, S. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00373-7 · Cited by 307
Pakshir, P., Noskovicova, N., Lodyga, M., Son, D. O., Schuster, R., Goodwin, A., Karvonen, H., & Hinz, B. (2020) · Journal of Cell Science · doi:10.1242/jcs.227900 · Cited by 293
Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis
Gao, J., Wei, B., de Assuncao, T. M., Liu, Z., Hu, X., Ibrahim, S., Cooper, S. A., Cao, S., Shah, V. H., & Kostallari, E. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.044 · Cited by 288
Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis
Cai, B., Dongiovanni, P., Corey, K. E., Wang, X., Shmarakov, I. O., Zheng, Z., Kasikara, C., Davra, V., Meroni, M., Chung, R. T., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.013 · Cited by 266
Wang, X., He, Q., Zhou, C., Xu, Y., Liu, D., Fujiwara, N., Kubota, N., Click, A., Henderson, P., Vancil, J., et al. (2023) · Immunity · doi:10.1016/j.immuni.2022.11.013 · Cited by 262
Yang, W., He, H., Wang, T., Su, N., Zhang, F., Jiang, K., Zhu, J., Zhang, C., Niu, K., Wang, L., et al. (2021) · Hepatology · doi:10.1002/hep.31987 · Cited by 250
Single-cell technologies in hepatology: new insights into liver biology and disease pathogenesis
Ramachandran, P., Matchett, K. P., Dobie, R., Wilson-Kanamori, J. R., & Henderson, N. C. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0304-x · Cited by 253
Self-citationA subset of Kupffer cells regulates metabolism through the expression of CD36
Blériot, C., Barreby, E., Dunsmore, G., Ballaire, R., Chakarov, S., Ficht, X., De Simone, G., Andreata, F., Fumagalli, V., Guo, W., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.006 · Cited by 236
Mechanical communication in fibrosis progression
Long, Y., Niu, Y., Liang, K., & Du, Y. (2022) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.10.002 · Cited by 233
Hendrikx, T., Porsch, F., Kiss, M. G., Rajcic, D., Papac-Miličević, N., Hoebinger, C., Goederle, L., Hladik, A., Shaw, L. E., Horstmann, H., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.004 · Cited by 220
Su, T., Yang, Y., Lai, S., Jeong, J., Jung, Y., McConnell, M., Utsumi, T., & Iwakiri, Y. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.12.007 · Cited by 220
XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis
Deczkowska, A., David, E., Ramadori, P., Pfister, D., Safran, M., Li, B., Giladi, A., Jaitin, D. A., Barboy, O., Cohen, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01344-3 · Cited by 197
Li, R.-Y., Qin, Q., Yang, H.-C., Wang, Y.-Y., Mi, Y.-X., Yin, Y.-S., Wang, M., Yu, C.-J., & Tang, Y. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00542-y · Cited by 204
Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis
Matsuda, M., & Seki, E. (2020) · Seminars in Liver Disease · doi:10.1055/s-0040-1708876 · Cited by 189
The evolving role of liver sinusoidal endothelial cells in liver health and disease
McConnell, M. J., Kostallari, E., Ibrahim, S. H., & Iwakiri, Y. (2023) · Hepatology · doi:10.1097/hep.0000000000000207 · Cited by 189
Principles of Cell Circuits for Tissue Repair and Fibrosis
Adler, M., Mayo, A., Zhou, X., Franklin, R. A., Meizlish, M. L., Medzhitov, R., Kallenberger, S. M., & Alon, U. (2020) · iScience · doi:10.1016/j.isci.2020.100841 · Cited by 177
Anstee, Q. M., Neuschwander-Tetri, B. A., Wai-Sun Wong, V., Abdelmalek, M. F., Rodriguez-Araujo, G., Landgren, H., Park, G. S., Bedossa, P., Alkhouri, N., Tacke, F., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.04.003 · Cited by 179
Self-citationA proteo-transcriptomic map of non-alcoholic fatty liver disease signatures
Govaere, O., Hasoon, M., Alexander, L., Cockell, S., Tiniakos, D., Ekstedt, M., Schattenberg, J. M., Boursier, J., Bugianesi, E., Ratziu, V., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00775-1 · Cited by 178
Single-cell RNA sequencing of human liver reveals hepatic stellate cell heterogeneity
Payen, V. L., Lavergne, A., Alevra Sarika, N., Colonval, M., Karim, L., Deckers, M., Najimi, M., Coppieters, W., Charloteaux, B., Sokal, E. M., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100278 · Cited by 160
Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)
Wang, S., & Friedman, S. L. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adi0759 · Cited by 158
Cell therapy for advanced liver diseases: repair or rebuild
Dwyer, B. J., Macmillan, M. T., Brennan, P. N., & Forbes, S. J. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.09.014 · Cited by 141
Multipotent stromal cells: One name, multiple identities
Soliman, H., Theret, M., Scott, W., Hill, L., Underhill, T. M., Hinz, B., & Rossi, F. M. V. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.09.001 · Cited by 147
A human multi-lineage hepatic organoid model for liver fibrosis
Guan, Y., Enejder, A., Wang, M., Fang, Z., Cui, L., Chen, S.-Y., Wang, J., Tan, Y., Wu, M., Chen, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26410-9 · Cited by 149
Heterogeneity of HSCs in a Mouse Model of NASH
Rosenthal, S. B., Liu, X., Ganguly, S., Dhar, D., Pasillas, M. P., Ricciardelli, E., Li, R. Z., Troutman, T. D., Kisseleva, T., Glass, C. K., et al. (2021) · Hepatology · doi:10.1002/hep.31743 · Cited by 145
Lipid-associated macrophages' promotion of fibrosis resolution during MASH regression requires TREM2
Ganguly, S., Rosenthal, S. B., Ishizuka, K., Troutman, T. D., Rohm, T. V., Khader, N., Aleman-Muench, G., Sano, Y., Archilei, S., Soroosh, P., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2405746121 · Cited by 145
“Although TREM2 has been shown to be up - regulated in advanced MASH livers ( 6 , 16 ), at what stage TREM2 is induced during the disease progression and what event (such as steatosis, fibrosis, or hepatocyte death) triggers TREM2 upregulation are not clear.”
InfluentialFuruta, K., Guo, Q., Pavelko, K. D., Lee, J.-H., Robertson, K. D., Nakao, Y., Melek, J., Shah, V. H., Hirsova, P., & Ibrahim, S. H. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143690 · Cited by 136
Multimodal decoding of human liver regeneration
Matchett, K. P., Wilson-Kanamori, J. R., Portman, J. R., Kapourani, C. A., Fercoq, F., May, S., Zajdel, E., Beltran, M., Sutherland, E. F., Mackey, J. B. G., et al. (2024) · Nature · doi:10.1038/s41586-024-07376-2 · Cited by 140
Self-citationLongevity and replenishment of human liver-resident memory T cells and mononuclear phagocytes
Pallett, L. J., Burton, A. R., Amin, O. E., Rodriguez-Tajes, S., Patel, A. A., Zakeri, N., Jeffery-Smith, A., Swadling, L., Schmidt, N. M., Baiges, A., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20200050 · Cited by 134
Molecular mechanisms in liver repair and regeneration: from physiology to therapeutics
Ma, X., Huang, T., Chen, X., Li, Q., Liao, M., Fu, L., Huang, J., Yuan, K., Wang, Z., & Zeng, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02104-8 · Cited by 133
Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis
Yu, J., Zhu, C., Wang, X., Kim, K., Bartolome, A., Dongiovanni, P., Yates, K. P., Valenti, L., Carrer, M., Sadowski, T., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe1692 · Cited by 132
Loft, A., Alfaro, A. J., Schmidt, S. F., Pedersen, F. B., Terkelsen, M. K., Puglia, M., Chow, K. K., Feuchtinger, A., Troullinaki, M., Maida, A., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.06.005 · Cited by 129
The Role of Sinusoidal Endothelial Cells in the Axis of Inflammation and Cancer Within the Liver
Wilkinson, A. L., Qurashi, M., & Shetty, S. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00990 · Cited by 121
Kupffer cell–like syncytia replenish resident macrophage function in the fibrotic liver
Peiseler, M., Araujo David, B., Zindel, J., Surewaard, B. G. J., Lee, W.-Y., Heymann, F., Nusse, Y., Castanheira, F. V. S., Shim, R., Guillot, A., et al. (2023) · Science · doi:10.1126/science.abq5202 · Cited by 123
Self-citationThe Emerging Role of B Cells in the Pathogenesis of NAFLD
Barrow, F., Khan, S., Wang, H., & Revelo, X. S. (2021) · Hepatology · doi:10.1002/hep.31889 · Cited by 126
Spatial transcriptomics of healthy and fibrotic human liver at single-cell resolution
Watson, B. R., Paul, B., Rahman, R. U., Amir-Zilberstein, L., Segerstolpe, Å., Epstein, E. T., Murphy, S., Geistlinger, L., Lee, T., Shih, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55325-4 · Cited by 123
Reich, M., Spomer, L., Klindt, C., Fuchs, K., Stindt, J., Deutschmann, K., Höhne, J., Liaskou, E., Hov, J. R., Karlsen, T. H., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.03.029 · Cited by 121
Understanding the cellular interactome of non-alcoholic fatty liver disease
Wallace, S. J., Tacke, F., Schwabe, R. F., & Henderson, N. C. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100524 · Cited by 116
Self-citationSavage, T. M., Fortson, K. T., de los Santos-Alexis, K., Oliveras-Alsina, A., Rouanne, M., Rae, S. S., Gamarra, J. R., Shayya, H., Kornberg, A., Cavero, R., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.01.009 · Cited by 120
Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models
Dai, H., Zhu, C., Huai, Q., Xu, W., Zhu, J., Zhang, X., Zhang, X., Sun, B., Xu, H., Zheng, M., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.01.034 · Cited by 114
Guillot, A., Winkler, M., Silva Afonso, M., Aggarwal, A., Lopez, D., Berger, H., Kohlhepp, M. S., Liu, H., Özdirik, B., Eschrich, J., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000270 · Cited by 116
Self-citationUnderstanding the heterogeneity of resident liver macrophages
Blériot, C., & Ginhoux, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02694 · Cited by 107
Kotsiliti, E., Leone, V., Schuehle, S., Govaere, O., Li, H., Wolf, M. J., Horvatic, H., Bierwirth, S., Hundertmark, J., Inverso, D., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.037 · Cited by 108
Self-citationNeuregulin 4 suppresses NASH-HCC development by restraining tumor-prone liver microenvironment
Zhang, P., Chen, Z., Kuang, H., Liu, T., Zhu, J., Zhou, L., Wang, Q., Xiong, X., Meng, Z., Qiu, X., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.010 · Cited by 105
Heterogeneity and Function of Kupffer Cells in Liver Injury
Li, W., Chang, N., & Li, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940867 · Cited by 102
Cellular plasticity balances the metabolic and proliferation dynamics of a regenerating liver
Chembazhi, U. V., Bangru, S., Hernaez, M., & Kalsotra, A. (2021) · Genome Research · doi:10.1101/gr.267013.120 · Cited by 102
Single-cell and bulk transcriptomics of the liver reveals potential targets of NASH with fibrosis
Wang, Z.-Y., Keogh, A., Waldt, A., Cuttat, R., Neri, M., Zhu, S., Schuierer, S., Ruchti, A., Crochemore, C., Knehr, J., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-98806-y · Cited by 103
BMP4 and Gremlin 1 regulate hepatic cell senescence during clinical progression of NAFLD/NASH
Baboota, R. K., Rawshani, A., Bonnet, L., Li, X., Yang, H., Mardinoglu, A., Tchkonia, T., Kirkland, J. L., Hoffmann, A., Dietrich, A., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00620-x · Cited by 99
The Multifaceted Roles of Macrophages in NAFLD Pathogenesis
Vonderlin, J., Chavakis, T., Sieweke, M., & Tacke, F. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.03.002 · Cited by 96
Self-citationMAIT cell inhibition promotes liver fibrosis regression via macrophage phenotype reprogramming
Mabire, M., Hegde, P., Hammoutene, A., Wan, J., Caër, C., Sayegh, R. A., Cadoux, M., Allaire, M., Weiss, E., Thibault-Sogorb, T., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37453-5 · Cited by 93
Lei, L., Bruneau, A., El Mourabit, H., Guégan, J., Folseraas, T., Lemoinne, S., Karlsen, T. H., Hoareau, B., Morichon, R., Gonzalez‐Sanchez, E., et al. (2022) · Hepatology · doi:10.1002/hep.32456 · Cited by 94
Self-citationSpatially restricted and ontogenically distinct hepatic macrophages are required for tissue repair
De Ponti, F. F., Bujko, A., Liu, Z., Collins, P. J., Schuermans, S., Maueroder, C., Amstelveen, S., Thoné, T., Martens, L., McKendrick, J. G., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.01.002 · Cited by 94
Self-citationFeng, D., Xiang, X., Guan, Y., Guillot, A., Lu, H., Chang, C., He, Y., Wang, H., Pan, H., Ju, C., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci166954 · Cited by 93
Self-citationSpatial transcriptomics identifies enriched gene expression and cell types in human liver fibrosis
Chung, B. K., Øgaard, J., Reims, H. M., Karlsen, T. H., & Melum, E. (2022) · Hepatology Communications · doi:10.1002/hep4.2001 · Cited by 85
Zhou, L., Wang, M., Guo, H., Hou, J., Zhang, Y., Li, M., Wu, X., Chen, X., & Wang, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.848367 · Cited by 85
Angiocrine signaling in sinusoidal homeostasis and liver diseases
Gao, J., Lan, T., Kostallari, E., Guo, Y., Lai, E., Guillot, A., Ding, B., Tacke, F., Tang, C., & Shah, V. H. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.05.014 · Cited by 90
Self-citationNicheformer: a foundation model for single-cell and spatial omics
Tejada-Lapuerta, A., Schaar, A. C., Gutgesell, R., Palla, G., Halle, L., Minaeva, M., Vornholz, L., Dony, L., Drummer, F., Richter, T., et al. (2025) · Nature Methods · doi:10.1038/s41592-025-02814-z · Cited by 100
Hepatic Stellate Cell-Immune Interactions in NASH
Carter, J. K., & Friedman, S. L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.867940 · Cited by 79
Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease
Wiering, L., Subramanian, P., & Hammerich, L. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.02.010 · Cited by 80
TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation
Labiano, I., Agirre-Lizaso, A., Olaizola, P., Echebarria, A., Huici-Izagirre, M., Olaizola, I., Esparza-Baquer, A., Sharif, O., Hijona, E., Milkiewicz, P., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.044 · Cited by 78
Immunopathogenic mechanisms and immunoregulatory therapies in MASLD
He, Y., Chen, Y., Qian, S., van Der Merwe, S., Dhar, D., Brenner, D. A., & Tacke, F. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01307-5 · Cited by 81
Self-citationInitiation of hepatic stellate cell activation extends into chronic liver disease
De Smet, V., Eysackers, N., Merens, V., Kazemzadeh Dastjerd, M., Halder, G., Verhulst, S., Mannaerts, I., & van Grunsven, L. A. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-04377-1 · Cited by 78
Cordero-Espinoza, L., Dowbaj, A. M., Kohler, T. N., Strauss, B., Sarlidou, O., Belenguer, G., Pacini, C., Martins, N. P., Dobie, R., Wilson-Kanamori, J. R., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.07.002 · Cited by 74
“A B C D Ramachandran et al., 2019).”
Self-citationSingle-nucleus RNA-seq2 reveals functional crosstalk between liver zonation and ploidy
Richter, M. L., Deligiannis, I. K., Yin, K., Danese, A., Lleshi, E., Coupland, P., Vallejos, C. A., Matchett, K. P., Henderson, N. C., Colome-Tatche, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24543-5 · Cited by 75
Self-citationGuo, Q., Furuta, K., Islam, S., Caporarello, N., Kostallari, E., Dielis, K., Tschumperlin, D. J., Hirsova, P., & Ibrahim, S. H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.983255 · Cited by 73
Gut-liver axis: Recent concepts in pathophysiology in alcohol-associated liver disease
Raya Tonetti, F., Eguileor, A., Mrdjen, M., Pathak, V., Travers, J., Nagy, L. E., & Llorente, C. (2024) · Hepatology · doi:10.1097/hep.0000000000000924 · Cited by 78
Coelho, I., Duarte, N., Barros, A., Macedo, M. P., & Penha-Gonçalves, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.616044 · Cited by 70
Metadata
- Authors
- Ramachandran, P., Dobie, R., Wilson-Kanamori, J. R., Dora, E. F., Henderson, B. E. P., Luu, N. T., Portman, J. R., Matchett, K. P., Brice, M., Marwick, J. A., Taylor, R. S., Efremova, M., Vento-Tormo, R., Carragher, N. O., Kendall, T. J., Fallowfield, J. A., Harrison, E. M., Mole, D. J., Wigmore, S. J., Newsome, P. N., Weston, C. J., Iredale, J. P., Tacke, F., Pollard, J. W., Ponting, C. P., Marioni, J. C., Teichmann, S. A., & Henderson, N. C.
- Affiliations
- Centre for Inflammation Research (GB)
- University Hospitals Birmingham NHS Foundation Trust (GB)
- Edinburgh Cancer Research (GB)
- Wellcome Sanger Institute (GB)
- Edinburgh Royal Infirmary (GB)
- National Institute for Health and Care Research (GB)
- Charité – Universitätsmedizin Berlin (DE)
- Albert Einstein College of Medicine (US)
- Institute of Genetics and Cancer (GB)
- European Bioinformatics Institute (GB)
- Corresponding author
- Ramachandran, P.
- Henderson, N. C.
- ORCID
- Ramachandran, P.
- Dobie, R.
- Henderson, B. E. P.
- Luu, N. T.
- Portman, J. R.
- Matchett, K. P.
- Brice, M.
- Taylor, R. S.
- Efremova, M.
- Carragher, N. O.
- Kendall, T. J.
- Fallowfield, J. A.
- Harrison, E. M.
- Mole, D. J.
- Wigmore, S. J.
- Newsome, P. N.
- Weston, C. J.
- Iredale, J. P.
- Tacke, F.
- Pollard, J. W.
- Ponting, C. P.
- Marioni, J. C.
- Teichmann, S. A.
- Henderson, N. C.
- Venue
- Nature
- Published
- 2019-10-09
- Volume
- 575
- Issue
- 7783
- Pages
- 512-518
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC6876711
- OpenAlex
- W2979595830
- Cited by
- 1,784
- References
- 98
- Citations by year
- 2026: 306 · 2025: 319 · 2024: 293 · 2023: 286 · 2022: 220 · 2021: 221 · 2020: 131 · 2019: 7
- FWCI
- 92.30
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Nature (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- Wellcome Trust (RE/18/5/34216, 103749, 101067/Z/13/Z, WT206194, 103749/Z/14/Z)
- University Hospitals Birmingham NHS Foundation Trust
- NIHR Bristol Biomedical Research Centre
- Cancer Research UK (22231)
- National Institute for Health and Care Research
- British Heart Foundation (RM/17/3/33381, RE/18/5/34216)
- Department of Health and Social Care
- Children's Liver Disease Foundation
- Tenovus
- University of Birmingham
- University of Bristol
- Medical Research Council (RM/17/3/33381, MC_PC_15049, MR/N008340/1, 103749, MC_PC_15075, MR/P008887/1, MC_UU_00007/15, MC_PC_15041, RE/18/5/34216, MR/N022556/1)
- Biotechnology and Biological Sciences Research Council (BB/N018869/1, RE/18/5/34216)
- Birmingham Biomedical Research Centre
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- liver cirrhosis, liver fibrosis, fibrotic niche, monocyte differentiation, collagen synthesis, TNFRSF12A, Notch signaling, non-parenchymal cells
- MeSH terms
- Animals, Duffy Blood-Group System, Female, Humans, Liver, Liver Cirrhosis, Macrophages, Male, Membrane Glycoproteins, Membrane Proteins, Phenotype, Receptors, Cell Surface, Receptors, Immunologic, Case-Control Studies, Cell Lineage, Receptor, Platelet-Derived Growth Factor alpha, Hepatocytes, Endothelial Cells, Mice, Hepatic Stellate Cells, Transendothelial and Transepithelial Migration, Single-Cell Analysis, Transcriptome, Tetraspanin 29
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
